Inhibition of Cav3.1 has been suggested as a novel target for Dravet syndrome as knockout of Cacna1g, which encodes Cav3.1, diminished spontaneous seizures and improved survival of Scn1a+/– mice (Calhoun et al., 2017). The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.